SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

A group of researchers says delayed treatment of a type of bird flu now spreading on dairy farms in the United States may ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and should even be effective against new strains ...

The Department of Public Health and Social Services encourages proactive approach to protect oneself and others from health ...

The first and most widely used single-dose antiviral flu pill is baloxavir marboxil, marketed as Xofluza and developed by the ...

Severe fever with thrombocytopenia syndrome (SFTS) was reported in Asia, with a fatality rate that can reach as high as 50%.

U.S. Antiviral Drugs Market to Surpass USD 27.07 Billion by 2032, Fueled by Chronic Infection Treatment Demand and Strong R&D Ecosystem.Austin, July 17, 2025 (GLOBE NEWSWIRE) -- Antiviral Drugs Market ...

A group of researchers from Japan's University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center said ...

The Department of Public Health and Social Services reminded the community that preventative measures like proper hygiene and ...

A new long-acting influenza drug by Cidara Therapeutics demonstrated up to 76% protection against symptomatic flu in a phase ...

The likelihood of antiviral prescribing and dispensing among patients with influenza varied by care setting, patient age, and underlying medical conditions.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...